Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany

Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany

Background: Monoclonal antibodies (mAb) have been introduced as a promising new therapeutic approach against SARS-CoV-2. At present, there is little experience regarding their clinical effects in patient populations underrepresented in clinical trials, e.g. immunocompromised patients. Additionally,...

Full description

Bibliographic Details
Main Authors: Bjoern Jensen, Nadine Luebke, Torsten Feldt, Verena Keitel, Timo Brandenburger, Detlef Kindgen-Milles, Matthias Lutterbeck, Noemi F Freise, David Schoeler, Rainer Haas, Alexander Dilthey, Ortwin Adams, Andreas Walker, Joerg Timm, Tom Luedde
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:The Lancet Regional Health. Europe
Online Access:http://www.sciencedirect.com/science/article/pii/S2666776221001411

Internet

http://www.sciencedirect.com/science/article/pii/S2666776221001411

Similar Items